Symbiotec Pharmalab Surges on Analyst Buy Calls

Symbiotec Pharmalab's stock experienced an upward trend after Motilal Oswal launched coverage with a "buy" recommendation and a target price of ₹1,430. The brokerage highlighted the company's successful transition from a steroidal API manufacturer to an integrated business model encompassing API, CDMO, and complex injectables. This strategic evolution is supported by substantial manufacturing investments and backward integration.

Motilal Oswal identified Symbiotec Pharmalab as a leading supplier in the corticosteroid/hormone API market, with significant expansion plans into fermentation-based and complex APIs. The company's foray into precision fermentation, industrial biotechnology, and biologics as a CDMO platform, alongside forward integration into double chamber vials, is expected to enhance profitability and market access, particularly in regulated markets like the US.

ICICI Direct also maintains a "buy" rating with a target of ₹1,540. Both firms project robust financial growth. Motilal Oswal forecasts revenue and EBITDA to grow at a 33% CAGR through FY2029, with PAT reaching ₹300 crore. Key growth drivers include new product launches, scaled CDMO and injectable operations, and operating leverage. Despite potential risks such as product concentration and competition, analysts remain optimistic.